 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 184
Date: August 12, 2024
Our recent article on how HuMax-CD20 works (A Smarter Monoclonal on Trial) was admittedly a “cartoon” version, but we were careful to check our facts with several heavy-weight experts before we published our review. I continue to think this new anti-CD20 will play an important role in the treatment of CLL patients.
Our ongoing dialogue with our advisory board has raised an additional issue worth noting, one that falls into the category of potential risk - especially in the context of the heavily pre-treated and refractory patients recruited for the Phase-3 HuMax-CD20 trial, patients who might also be significantly immune compromised going into this trial. If, like me, you like being safe rather than sorry, you will want to read our latest article: HuMax-CD20: Risks and Rewards.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
